| Viewics–Roche: investment, 201711 acquisition of Viewics Inc by Roche |
2017-11-17 |
| Viela Bio–SEVERAL: investment, 201802 up to $250m funding from investor consortium at spin-out with AZ remaining largest minority shareholder |
2018-02-28 |
| Vico Therapeutics–SEVERAL: investment, 2019Q4–202007 financing round Series A €27m led by LSP + co-led by Kurma Partners |
2019-12-31 |
| Vico Therapeutics–Pontifax: investment, 2019Q4–202007 financing round Series A totalling €27m incl co-investor Pontifax |
2019-12-31 |
| Vico Therapeutics–Polaris Partners: investment, 2019Q4–202007 financing round Series A totalling €27m incl co-investor Polaris Partners |
2019-12-31 |
| Vico Therapeutics–LifeSpring: public relations, 202007 service existent by LifeSpring Communications |
2020-07-29 |
| Vico Therapeutics–Life Sciences Partners: investment, 2019Q4–202007 financing round Series A totalling €27m incl lead investor LSP |
2019-12-31 |
| Vico Therapeutics–Eurazeo: investment, 2019Q4–202007 financing round Series A totalling €27m incl co-lead investor Kurma Partners |
2019-12-31 |
| Vico Therapeutics–Eurazeo: investment, 2019Q4–202007 financing round Series A totalling €27m incl co-investor Idinvest Partners |
2019-12-31 |
| Vico Therapeutics–Droia Ventures: investment, 2019Q4–202007 financing round Series A totalling €27m incl co-investor Droia Genetic Disease Fund |
2019-12-31 |
| Vico Therapeutics–Bellevue: investment, 2019Q4–202007 financing round Series A totalling €27m incl co-investor Pureos Bioventures |
2019-12-31 |
| VIB–Resolve Biosciences: Molecular Cartography technology, 202210 supply to VIB existent as one of first customers |
2022-10-24 |
| VIB–Lipotype: mass spectrometry services, 2015– collab supply of shotgun lipidomics services by Lipotype to researchers at VIB |
2015-01-01 |
| ViaNautis Bio–UCB: investment, 202311 financing round Series A totalling $25m incl co-lead investor UCB Ventures |
2023-11-13 |
| ViaNautis Bio–SEVERAL: investment, 202311 financing round Series A $25m led by 4BIO Capital + BGF + UCB Ventures |
2023-11-13 |
| ViaNautis Bio–Origin Capital: investment, 202311 financing round Series A totalling $25m incl exisitng + co-investor Origin Capital |
2023-11-13 |
| ViaNautis Bio–o2h: investment, 202311 financing round Series A totalling $25m incl exisitng + co-investor O2H |
2023-11-13 |
| ViaNautis Bio–Meltwind: investment, 202311 financing round Series A totalling $25m incl exisitng + co-investor Meltwind |
2023-11-13 |
| ViaNautis Bio–Cystic Fibrosis Foundation: investment, 202311 financing round Series A totalling $25m incl co-investor Cystic Fibrosis Foundation |
2023-11-13 |
| ViaNautis Bio–BGF: investment, 202311 financing round Series A totalling $25m incl co-lead investor BGF |
2023-11-13 |
| ViaNautis Bio–4BIO Ventures: investment, 202311 financing round Series A totalling $25m incl co-lead investor 4BIO Capital |
2023-11-13 |
| Vesigen Therapeutics–SEVERAL: investment, 202007 financing round Series A $28.5m co-led by Leaps by Bayer + Morningside Ventures |
2020-07-22 |
| Vesigen Therapeutics–Morningside: investment, 202007 financing round Series A totalling $28.5m incl co-lead investor Morningside Ventures |
2020-07-22 |
| Vesigen Therapeutics–Linden Lake Venture Capital: investment, 202007 financing round Series A totalling $28.5m incl co-investor Linden Lake VC |
2020-07-22 |
| Vesigen Therapeutics–Bayer: investment, 202007 financing round Series A totalling $28.5m incl co-lead investor Leaps by Bayer |
2020-07-22 |
| Vesigen Therapeutics–Alexandria Real Estate: investment, 202007 financing round Series A totalling $28.5m incl co-investor Alexandria Venture |
2020-07-22 |
| Vesalius Biocapital–SEVERAL: investment, 201906 final closing of €120m Vesalius Biocapital III fund |
2019-06-25 |
| Vesalius Biocapital–SEVERAL: investment, 201705 first closing €65m of Vesalius Biocapital III fund |
2017-05-15 |
| Vésale Bioscience–EU (govt): grant, 202301 EIC Accelerator grant €1.8m for develpment of PhageDiag phagogramme |
2023-01-17 |
| Vésale Bioscience–Andrew Lloyd Associates: public relations, 202301 service existent by ALA |
2023-01-17 |
| Verve Capital Partners–SEVERAL: investment, 202206 1st CHF45m closing of Verve Venture Fund I |
2022-06-24 |
| Vertex–Genomics plc: bioinformatics, 201808– collab expansion using human genetics + data science for target discovery + personalised medicine |
2018-08-30 |
| Vertex–CRISPR Therapeutics: CRISPR technology, 202303– license non-excl $100m upfront + $230m milestones + royalties CRISPR/Cas9 for cell therapies |
2023-03-27 |
| Vertex–CRISPR Therapeutics: CRISPR technology, 201906– collab expansion $175m upfront + $825m milestones CRISPR for DMD + DM1 gene editing products |
2019-06-06 |
| Vertama–SEVERAL: investment, 202307 seed financing round 7-digit € led by HTGF |
2023-07-12 |
| Vertama–OTHER: investment, 202307 seed financing round totalling 7-digit € incl renowned business angels |
2023-07-12 |
| Vertama–High-Tech Gründerfonds: investment, 202307 seed financing round totalling 7-digit € incl lead investor HTGF |
2023-07-12 |
| Vertama–BACB: investment, 202307 seed financing round totalling 7-digit € incl investor Berlin Angel Fund |
2023-07-12 |
| Versum Materials–Merck (DE): investment, 201902– unsolicited all-cash offer at $48/share by Merck |
2019-02-27 |
| Versantis–SEVERAL: investment, 201909 financing round Series B CHF16m led by Swisscanto Invest by ZKB |
2019-09-18 |
| Versantis–SEVERAL: investment, 201703 financing round Series A CHF4.4m led by Redalpine Venture Partners |
2017-03-29 |
| Versantis–Halsin Partners: public relations, 201909 service existent by Halsin Partners |
2019-09-17 |
| Versantis–Genfit: investment, 202209– acquisition CHF40m upfront + CHF65m milestones + 1/3 of net proceeds of eventual PRV |
2022-09-19 |
| Versanis Bio–Lilly: investment, 202307– acquisition up to $1.925b |
2023-07-01 |
| Versanis Bio–Forbion: investment, 202307 existent shareholder Forbion |
2023-07-01 |
| Versameb–SEVERAL: investment, 201910 seed C financing round CHF6.4m bringing total capital raised to CHF11.8m |
2019-10-17 |
| Versameb–SEVERAL: investment, 201812 colsing of seed B financing round brining total capital raised to date to CHF5.3m |
2018-12-18 |
| VeroVaccines–SEVERAL: investment, 202110 financing round Series B mid-7-figure € from consortium of investors from Germany + Switzerland |
2021-10-14 |
| Verona Pharma–SEVERAL: investment, 201704 US IPO $78m with 5.768m ADSs at $13.5/ADS at Nasdaq Global Market |
2017-04-04 |
| Verona Pharma–Novo Group: investment, 201903 existent investment Novo Holdings owns 11.76% shareholding in Verona Pharma plc |
2019-03-21 |
| Verona Pharma–LCF Rothschild: investment, 201607 investment by EdRIP |
2016-07-01 |
| Verona Pharma–ICR: public relations, 201903 service existent by ICR in US |
2019-03-21 |
| Verona Pharma–Arix Bioscience: investment, 2017 investment £1.8m during 2017 from existing investor Arix results in shareholding of 2.5% |
2017-01-01 |
| Verogen–Qiagen: investment, 202301c full acquisition of Verogen for $150m in cash |
2023-01-09 |
| Vernalis–Ligand: investment, 201808– recommended cash takeover offer £32.8m with £0.062/share ANNOUNCED |
2018-08-09 |
| Verdel Instruments–United Kingdom (govt): investment, 201905 seed financing round totalling £230k incl investor Innovate UK |
2019-05-30 |
| Verdel Instruments–SEVERAL: investment, 201905 seed financing round £230k from Longwall Venture Partners + Innovate UK |
2019-05-30 |
| Verdel Instruments–Longwall Venture Partners: investment, 201905 seed financing round totalling £230k incl £100k from Longwall Ventures |
2019-05-30 |
| Vera Therapeutics–Merck (DE): investment, 202011 Merck reveices 10% equity in Vera Tx as part of license deal for atacicept |
2020-11-09 |
| Vera Therapeutics–Merck (DE): atacicept, 202011– license for 10% equity in Vera + €605m milestones + royalties |
2020-11-09 |
| Vera Therapeutics–Abingworth: investment, 202102 investment existent by Abingworth Bioventures 8 |
2021-02-03 |
| Ventyx Biosciences–SEVERAL: investment, 202103 financing round $114m led by VenBio Partners |
2021-03-09 |
| Ventech–SEVERAL: investment, 201803 first closing €140m of Ventech Capital V fund with €200m target size |
2018-03-07 |
| VenBio–UDG Healthcare: public relations, 202004 service existent by Canale Communciations |
2020-04-03 |
| Veloxis Pharmaceuticals–Asahi Kasei: investment, 201911– recommended cash offer DKK 8.9b ($1.3b) by Asahi Kasei Pharma Denmark A/S |
2019-11-25 |
| VelosBio–Takeda: investment, 201810 financing round Series A totalling $58m incl existing + co-investor Takeda Ventures Inc |
2018-10-01 |
| VelosBio–Sofinnova: investment, 201810 financing round Series A totalling $58m incl new + co-lead investor Sofinnova Ventures |
2018-10-01 |
| VelosBio–SEVERAL: investment, 201810 financing round Series A $58m co-led by new investors Arix Bioscience + Sofinnova Ventures |
2018-10-01 |
| VelosBio–Merck (US): investment, 202011–202012 acquisition $2.75b in cash of VelosBio by Merck |
2020-11-05 |
| VelosBio–Decheng Capital: investment, 201810 financing round Series A totalling $58m incl existing + co-investor Decheng Capital |
2018-10-01 |
| VelosBio–Chiesi: investment, 201810 financing round Series A totalling $58m incl new + co-investor Chiesi Ventures |
2018-10-01 |
| VelosBio–Arix Bioscience: investment, 201810 financing round Series A totalling $58m incl $11m from new + co-lead investor Arix Bioscience |
2018-10-01 |
| VelosBio–AM Pappas: investment, 201810 financing round Series A totalling $58m incl new + co-investor Pappas Ventures |
2018-10-01 |
| Velabs Therapeutics–SEVERAL: investment, 201906 financing round Series B €3m |
2019-06-27 |
| Velabs Therapeutics–Alytas Therapeutics: therapeutic antibodies, 202001– license excl for developm + commercialisation of Abs in field of senescence |
2020-01-07 |
| Vedere Bio–SEVERAL: investment, 201906 financing round Series A $21m |
2019-06-01 |
| Vedere Bio–Novartis: investment, 202009 acquisition $150m upfront + $130m milestones with some assets spun out before into Vedere BIo II |
2020-09-30 |
| Vedanta Biosciences–SEVERAL: investment, 201812 financing round Series C $27m Gates + BMS + Rock Springs Capital + Invesco + Seventure + PureTech |
2018-12-24 |
| Vedanta Biosciences–Rock Springs Capital: investment, 201812 financing round Series C totalling $27m incl existing investor Rock Springs Capital |
2018-12-24 |
| Vedanta Biosciences–Rock Springs Capital: investment, 201606 financing round totalling $50m incl new investor Rock Springs Capital |
2016-06-06 |
| Vedanta Biosciences–PureTech Health: investment, 201812 financing round Series C totalling $27m incl existing investor PureTech Health |
2018-12-24 |
| Vedanta Biosciences–PureTech Health: investment, 201606 financing round totalling $50m incl investor PureTech Health plc |
2016-06-06 |
| Vedanta Biosciences–Invesco: investment, 201812 financing round Series C totalling $27m incl existing investor Invesco Asset Management |
2018-12-24 |
| Vedanta Biosciences–Invesco: investment, 201606 financing round totalling $50m incl new investor Invesco Asset Management |
2016-06-06 |
| Vedanta Biosciences–Gates Foundation: investment, 201812 financing round Series C totalling $27m incl new investor Gates Foundation |
2018-12-24 |
| Vedanta Biosciences–BPCE: investment, 201812 financing round Series C totalling $27m incl existing investor Seventure Partners |
2018-12-24 |
| Vedanta Biosciences–BPCE: investment, 201606 financing round totalling $50m incl new investor Health for Life Capital (Seventure) |
2016-06-06 |
| Vedanta Biosciences–BMS: investment, 201812 financing round Series C totalling $27m incl new investor BMS |
2018-12-24 |
| Vectura–Philip Morris: investment, 202107– acquisition recommended cash tender offer £852m at150p/share |
2021-07-09 |
| VectorY–SEVERAL: investment, 202311 financing round Series A €129m co-led by EQT Life Sciences + Forbion Growth Opportunities Fund |
2023-11-13 |
| VectorY–SEVERAL: investment, 202106 seed financing round €31m co-led by Forbion + leading global investment firm |
2021-06-15 |
| VectorY–OTHER: investment, 202311 financing round Series A totalling €129m incl another known investor |
2023-11-13 |
| VectorY–OTHER: investment, 202106 seed financing round totalling €31m incl co-lead investor leading global investment firm |
2021-06-15 |
| VectorY–Merck (US): investment, 202311 financing round Series A totalling €129m incl co-investor MRL Ventures Fund |
2023-11-13 |
| VectorY–Lilly: investment, 202106 seed financing round totalling €31m incl co-investor Eli Lilly |
2021-06-15 |
| VectorY–Instinctif Partners: public relations, 202106 service existent by Instinctif |
2021-06-15 |
| VectorY–Insight Partners: investment, 202311 financing round Series A totalling €129m incl co-investor Insight Partners |
2023-11-13 |
| VectorY–Forbion: investment, 202311 financing round Series A totalling €129m incl existing + co-lead investor Forbion GOF + Forbion Ventures |
2023-11-13 |
| VectorY–Forbion: investment, 202106 seed financing round totalling €31m incl co-lead + founding investor Forbion |
2021-06-15 |
| VectorY–Forbion: investment, 202008 founding + seed investor Forbion |
2020-08-01 |
![[LSE] Life-Sciences-Europe.com - The European Life Sciences Web Portal](/images/basics/lse-life-sciences-europe-portal-logo.svg){kind=logo}
1 2 3 4 ... 95 96 97 
Deal: Collaboration or Financing
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20230710-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
